Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.55 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.40 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 3/20 | 0.35 |
| ▸ | DRD3 | P35462 | 3/20 | 0.35 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL229239 | 0.92 | ESR1 (0.48) | ESR1ESR2GRIN2BGRIN1CYP26A1 | |
| SCHEMBL229714 | 0.88 | ESR1 (0.50) | ESR1ESR2POLBKMT2AGRIN2B | |
| SCHEMBL228364 | 0.87 | ESR1 (0.56) | ESR1ESR2POLBKMT2AGRIN2B | |
| SCHEMBL228664 | 0.87 | ESR1 (0.56) | ESR1ESR2POLBKMT2AGRIN2B | |
| SCHEMBL3996726 | 0.87 | ESR1 (0.56) | ESR1ESR2POLBKMT2AGRIN2B | |
| SCHEMBL230234 | 0.87 | ESR1 (0.53) | ESR1ESR2POLBKMT2AGRIN2B | |
| SCHEMBL225074 | 0.86 | ESR1 (0.45) | ESR1ESR2KMT2AGRIN2BGRIN1 | |
| SCHEMBL229205 | 0.86 | ESR1 (0.57) | ESR1ESR2POLBKMT2AGRIN2B | |
| SCHEMBL225502 | 0.86 | ESR1 (0.49) | ESR1ESR2CYP26A1ADRA1DADRA1A | |
| SCHEMBL228197 | 0.86 | ESR1 (0.59) | ESR1ESR2POLBKMT2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8933130-B2 | Treatment of vasomotor symptoms with selective estrogen receptor modulators | RADIUS HEALTH, INC. (US) | 2015-01-13 | — | — | US | claimed |
| EP-1577288-B1 | Selective estrogen receptor modulators | EISAI R&D MAN CO LTD (JP) | 2014-07-23 | — | — | EP | claimed |
| EP-2037905-B1 | TREATMENT OF VASOMOTOR SYMPTOMS WITH SELECTIVE ESTROGEN RECEPTOR MODULATORS | RADIUS HEALTH INC (US) | 2013-05-01 | — | — | EP | claimed |
| US-20100105733-A1 | Treatment of vasomotor symptoms with selective estrogen receptor modulators | RADIUS HEALTH, INC. | 2010-04-29 | — | — | US | claimed |
| US-7612114-B2 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-03 | — | — | US | claimed |
| EP-2037905-A2 | TREATMENT OF VASOMOTOR SYMPTOMS WITH SELECTIVE ESTROGEN RECEPTOR MODULATORS | Radius Health, Inc. (US) | 2009-03-25 | — | — | EP | claimed |
| WO-2008002490-A2 | TREATMENT OF VASOMOTOR SYMPTOMS WITH SELECTIVE ESTROGEN RECEPTOR MODULATORS | RADIUS HEALTH, INC. (US) | 2008-01-03 | — | — | WO | claimed |
| US-8933130-B2 | Treatment of vasomotor symptoms with selective estrogen receptor modulators | RADIUS HEALTH, INC. (US) | 2015-01-13 | — | — | US | disclosed |
| EP-1577288-B1 | Selective estrogen receptor modulators | EISAI R&D MAN CO LTD (JP) | 2014-07-23 | — | — | EP | disclosed |
| EP-2037905-B1 | TREATMENT OF VASOMOTOR SYMPTOMS WITH SELECTIVE ESTROGEN RECEPTOR MODULATORS | RADIUS HEALTH INC (US) | 2013-05-01 | — | — | EP | disclosed |
| US-8399520-B2 | Selective estrogen receptor modulator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-03-19 | — | — | US | disclosed |
| US-20120004315-A1 | Selective Estrogen Receptor Modulator | RADIUS HEALTH, INC. | 2012-01-05 | — | — | US | disclosed |
| US-7960412-B2 | Selective estrogen receptor modulator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20100105733-A1 | Treatment of vasomotor symptoms with selective estrogen receptor modulators | RADIUS HEALTH, INC. | 2010-04-29 | — | — | US | disclosed |
| US-20090325930-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATOR | RADIUS HEALTH, INC. | 2009-12-31 | — | — | US | disclosed |
| US-7612114-B2 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-03 | — | — | US | disclosed |
| US-20060116364-A1 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | EISAI CO., LTD. (JP) | 2006-06-01 | — | — | US | disclosed |
| EP-1577288-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | Eisai Co., Ltd. (JP) | 2005-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325930-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATOR | ESR1, GPER1, ESR2 | ESR1 1/4885ESR2 3/4885POLB 3238/4885 |
| US-20100105733-A1 | Treatment of vasomotor symptoms with selective estrogen receptor modulators | GPER1, ESR1, SHBG | ESR1 2/4885ESR2 4/4885POLB 4777/4885 |
| US-20060116364-A1 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | BRCA1, BCR, RCC1 | ESR1 34/4885ESR2 21/4885POLB 2092/4885 |
| US-20120004315-A1 | Selective Estrogen Receptor Modulator | ESR1, GPER1, ESR2 | ESR1 1/4885ESR2 3/4885POLB 3007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.